

35 (Amended). [The use of] A method for upregulating the presentation of an antigen or antigenic determinant by MHC class I molecules upon administration of the antigen or antigenic determinant to a mammalian subject comprising administering to the subject an effective amount of a conjugate with antigen or antigenic determinant and an immunomodulator selected from the group consisting of:


- 5
- (i) EtxB, CtxB or VtxB free from whole toxin;
 - (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; [or] and
 - (iii) an agent which has an effect on vesicular internalisation mediated by
- 10 GM1-binding or Gb3 binding[;
- in a conjugate with antigen or antigenic determinant to upregulate the presentation of said antigenic determinant, or an antigenic determinant derived from said antigen, by MHC class I molecules].

REMARKS

Claims 1 to 37 were pending in this application in its published PCT format. Claims 1 to 23 and 31 to 35 were amended to convert use claims to method claims employed in the U.S. Claims 3, 6, 7, 8, 12, 14, 16, 18, 20, and 23 were further amended to save considerable fees by re-writing multiple dependent claims as dependent claims. As amended, the application has 37 claims, 11 of which are independent, and no multiple dependent claims.

The claimed invention provides significant new ways of enhancing the efficacy of vaccines. Applicants therefore request early and favorable consideration of the claims. If the undersigned can advance the prosecution of this application in any way, the Examiner is invited to call at the number listed below.

Respectfully submitted,


MARY M. KRINSKY, Reg. No. 32423
79 Trumbull Street
New Haven, Connecticut 06511-3708
(203) 773-9544